Search Result

Results for "

human epidermal growth factor receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (28) IGF-1R (2) ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (4) Bcl-2 Family (1) Calcium Channel (2) Caspase (1) CDK (1) Cytochrome P450 (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) ERK (2) FAK (1) Fluorescent Dye (1) LDLR (2) Mitosis (2) mRNA (3) PACAP Receptor (2) PD-1/PD-L1 (2) Proteasome (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) Src (1) Thymidylate Synthase (1) TSPO (1)
By Research Areas:	Cancer (33) Infection (1) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	mRNA (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: EGFR FGFR GHR VEGFR TGF-β Receptor PDGFR IGF-1R GHSR TGF-beta/Smad Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9905

Cetuximab 50+ Cited Publications C225; IMC-C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-138298

Trastuzumab deruxtecan (solution) 5 Publications Verification T-DXd (solution); DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298A

Trastuzumab deruxtecan 5 Publications Verification T-DXd; DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-P9985

Disitamab vedotin 5 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-164202

ORM-5029	Antibody-Drug Conjugates (ADCs)	Cancer
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 exhibits robust efficacy across 14 HER2-positive breast cancer cell lines, with IC₅₀ values ranging from 0.3 to 14.4 nM.ORM-5029 demonstrates anti-tumor activity in the BT474 xenograft model. ORM-5029 can be used for study of breast cancer .

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human Her2 and a K_a of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .

HY-P99941

Retifanlimab INCMGA-00012; MGA-012	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

HY-P10697A

VH4127 TFA	LDLR	Metabolic Disease
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-129510

4-Methyl erlotinib	EGFR Mitosis	Cancer
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-164527

Si306	Src FAK EGFR	Cancer
Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .

HY-160087

SG3376	EGFR Drug-Linker Conjugates for ADC	Cancer
SG3376 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). SG3376 is promising for research of HER2-overexpressing cancers (e.g., breast, gastric cancer) .

HY-P10697

VH4127	LDLR	Metabolic Disease
VH4127 is a cyclic peptide targeting the *low density lipoprotein receptor* (LDLR) with a K_D** of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-164487

JBJ-08-178-01	Proteasome	Cancer
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .

HY-172820

Trastuzumab envedotin DP303c	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-174535

Human TGFA mRNA	mRNA	Cancer
Human TGFA mRNA encodes the human transforming growth factor alpha (TGFA) protein. TGFA is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development.

HY-174841

EGFR/HER2-IN-19	EGFR	Cancer
EGFR/HER2-IN-19 (Compound L1) is a dual inhibitor against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-19 is promising for research of cancers driven by EGFR/HER2 .

HY-160613

EGFR/HER2-IN-11	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-174779

Human AREG mRNA	mRNA	Cancer
Human AREG mRNA encodes the human amphiregulin (AREG) protein, a member of the epidermal growth factor family. AREG interacts with the EGF/TGF-alpha receptor to promote the growth of normal epithelial cells, and inhibits the growth of certain aggressive carcinoma cell lines. It also functions in mammary gland, oocyte and bone tissue development.

HY-172623

EGFR/HER2-IN-17	EGFR Caspase Apoptosis Bcl-2 Family	Cancer
EGFR/HER2-IN-17 (Compound 7h) is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-17 inhibits cancer cell proliferation. EGFR/HER2-IN-17 interacts with the binding pockets of EGFR and HER2, activating caspase-3 and caspase-8, and decreases the expression of Bcl-2, thereby inducing apoptosis. EGFR/HER2-IN-17 is promising for research of cancers .

HY-172534

BPN-01	Fluorescent Dye EGFR TSPO	Cancer
BPN-01 is a fluorescent probe targeting translocator protein (TSPO) and human epidermal growth factor receptor 2 (HER2) with binding affinities of -10.7 kcal/mol for TSPO and -11.3 kcal/mol for HER2. BPN-01 is promising for research of solid tumor imaging during fluorescence image-guided surgery (FIGS) (Ex/Em = 475/510 nm) .

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-129510R

4-Methyl erlotinib (Standard)	EGFR Mitosis Reference Standards	Cancer
4-Methyl erlotinib (Standard) is the analytical standard of 4-Methyl erlotinib. This product is intended for research and analytical applications. 4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-146239

EGFR/HER2/TS-IN-2	EGFR Thymidylate Synthase	Cancer
EGFR/HER2/TS-IN-2 (compound 17) is a potent EGFR/HER2 and TS (Thymidylate synthase) inhibitor, with IC₅₀ values of 0.173, 0.125, and 1.12 μM, respectively. EGFR/HER2/TS-IN-2 shows cytotoxic activity against MDA-MB-231 cancer cell lines, with an IC₅₀ of 1.69 µM .

HY-110333

BMS-599626 dihydrochloride	EGFR	Cancer
BMS-599626 dihydrochloride is a small molecule pan-HER (human epidermal growth factor receptor) kinase inhibitor. BMS-599626 dihydrochloride primarily targets HER1 (IC₅₀=20 nmol/L) and HER2 (IC₅₀=30 nmol/L) kinase activity in the HER family. BMS-599626 inhibits the kinase activity of HER1 and HER2 by competing with their ATP-binding sites, and can inhibit the downstream signaling pathway by blocking the heterodimer formation of HER1 and HER2. BMS-599626 dihydrochloride can be used to study the antitumor effects of multiple HER1 or HER2 overexpressed tumor models .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

HY-174721

Human EGFR mRNA	mRNA	Cancer
Human EGFR mRNA encodes the human epidermal growth factor receptor (EGFR) protein, a member of the protein kinase superfamily. IGF1R plays a critical role in transformation events. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation.

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

HY-172160

HER2-IN-21	EGFR	Cancer
HER2-IN-21 (compound 657994) is a human epidermal growth factor receptor 2 (HER2) inhibitor, with an IC₅₀ of 3.85 μM .

HY-181142

Antitumor agent-213	EGFR Apoptosis	Cancer
Antitumor agent-213 is an antitumor agent. Antitumor agent-213 binds to epidermal growth factor receptor (EGFR) and shows antitumor activity. Antitumor agent-213 can inhibit cancer cells proliferation, migration and induces apoptosis. Antitumor agent-213 can be used for the research of cancer, such as liver cancer .

HY-181166

EGFR-IN-194	EGFR Apoptosis	Cancer
EGFR-IN-194 is a potent EGFR tyrosine kinase inhibitor with an IC₅₀ of 54.3 nM against human EGFR. EGFR-IN-194 induces apoptosis, inhibits migration in cancer cells, selectively promotes invasion in cancer cells, and exhibits antiproliferative effects across multiple cancer cell lines. EGFR-IN-194 can be used for the research of prostate adenocarcinoma, non-small cell lung carcinoma, breast carcinoma, chronic myeloid leukemia .

HY-182264

Masoprocol tetrapivalate Nordihydroguaiaretic acid tetrapivalate	IGF-1R EGFR Drug Metabolite	Cancer
Masoprocol tetrapivalate (Nordihydroguaiaretic acid tetrapivalate) is a catecholic butane metabolite and also a tyrosine kinase activity inhibitor of IGF-1R and EGFR. Masoprocol tetrapivalate regulates tyrosine kinase signaling pathways associated with cell proliferation. Masoprocol tetrapivalate can be used in the research of proliferative diseases, including malignant, precancerous or benign cancers, and solid tumors .

HY-181923

IMP-Zn	EGFR CDK Cytochrome P450	Cancer
IMP-Zn is a pyrazole-hydrazone Schiff base zinc (II) complex. IMP-Zn exhibits significant antiproliferative activity against human colorectal cancer cells and induces cell cycle arrest. IMP-Zn shows stronger binding affinity than its free ligand IMP towards three cancer-related protein targets: EGFR kinase 1M17, cytochrome P450 3RUK, and CDK inhibitor 6GUE. IMP-Zn can be used in studies related to colorectal cancer .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library	3,181 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-138298

Trastuzumab deruxtecan (solution) 5 Publications Verification T-DXd (solution); DS-8201 (solution); DS-8201a (solution)	Fluorescent Dyes
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

Trastuzumab deruxtecan (solution)

5 Publications Verification

T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

Fluorescent Dyes

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298A

Trastuzumab deruxtecan 5 Publications Verification T-DXd; DS-8201; DS-8201a	Fluorescent Dyes
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

Trastuzumab deruxtecan

5 Publications Verification

T-DXd; DS-8201; DS-8201a

Fluorescent Dyes

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-172820

Trastuzumab envedotin DP303c	Fluorescent Dyes
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

Trastuzumab envedotin

DP303c

Fluorescent Dyes

Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

Cat. No.	Product Name	Target	Research Area

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P10697A

VH4127 TFA	LDLR	Metabolic Disease
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P10697

VH4127	LDLR	Metabolic Disease
VH4127 is a cyclic peptide targeting the *low density lipoprotein receptor* (LDLR) with a K_D** of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9905

Cetuximab 50+ Cited Publications C225; IMC-C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human Her2 and a K_a of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .

HY-P99941

Retifanlimab INCMGA-00012; MGA-012	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

Species:	Human (29)
Tag:	His (19) Strep (6) Tag Free (3) Avi (1) Myc (1) GST (14) Fc (4)
Source:	HEK293 (11) sf9 insect cells (5) Sf9 insect cells (12) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P700485

	EPS15 Protein, Human (His) Eps15 epidermal; growth factor receptor pathway substrate 15; 2410112D09Rik; epidermal growth factor receptor substrate 15; epidermal growth factor pathway substrate 15; protein AF-1p	Human	E. coli
	EPS15 is a multifunctional protein that regulates cell growth, controls mitotic signaling, and contributes to receptor tyrosine kinase (RTK) internalization, particularly affecting EGFR. As a clathrin adapter, EPS15 is critical for the assembly and maturation of clathrin-coated pits (CCP), affecting the endocytosis of molecules such as ITGB1 and transferrin receptor (TFR). EPS15 Protein, Human (His) is the recombinant human-derived EPS15 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuepidermal growth factor receptor/EGFR vIII, His; epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72987

	EGFR Protein, Human (Active, sf9, His-GST) 2 Publications Verification epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	EGFR is a transmembrane glycoprotein. EGFR binds to ligands, triggering receptor dimerization, inducing intracellular TK domain autophosphorylation, activating downstream Ras/MAPK, PI3K/Akt and other signaling pathways, and regulating cell proliferation, survival, migration and angiogenesis. EGFR Protein, Human (sf9, His-GST) is a recombinant EGFR protein expressed by Sf9 insect cells with N-His, N-GST tags.

HY-P704578

	EGFR Protein, Human (621a.a, HEK293) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293) is the recombinant human-derived EGFR protein, expressed by HEK293, with tag free.

HY-P74177

	EGFR Protein, Human (621a.a, HEK293, Fc) 1 Publications Verification epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73517

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag.

HY-P704197

	EGFR Protein, Human (Active, L861Q, sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (L861Q, sf9, GST) is the recombinant human-derived EGFR protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704576

	EGFR Protein, Human (621a.a, HEK293, Llama Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, Llama Fc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Llama Fc labeled tag.

HY-P704574

	FITC-Labeled EGFR Protein, Human (621a.a, HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. FITC-Labeled EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived FITC-Labeled EGFR protein, expressed by HEK293, with C-His labeled tag.

HY-P705016

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, Fc-Avi) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293

HY-P705815

	EGFR Protein, Human (Active, G719C, sf9, His-GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	sf9 insect cells

HY-P700409

	EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

HY-P705811

	EGFR Protein, Human (Active, G719S, sf9, Strep-GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	sf9 insect cells

HY-P705812

	EGFR Protein, Human (Active, A763_Y764insFHEA, sf9, Strep-GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	sf9 insect cells

HY-P705813

	EGFR Protein, Human (Active, A763_Y764insFQEA, sf9, Strep-GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	sf9 insect cells

HY-P70608

	EGFR vIII Protein, Human (HEK293, Fc) 1 Publications Verification epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR vIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P706036

	EGFR Protein, Human (Active, 327a.a, sf9) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P702831

	EGFR Protein, Human (Active, C797S, T790M, L858R, sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (C797S, T790M, L858R, sf9, GST) is the recombinant human-derived EGFR, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P702832

	EGFR Protein, Human (Active, T790M, L858R, sf9, Strep II, GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (T790M, L858R, sf9, Strep II, GST, His) is the recombinant human-derived EGFR, expressed by Sf9 insect cells, with C-8*His, N-GST, N-Strep II labeled tag.

HY-P706038

	EGFR Protein, Human (Active, C797S, sf9, His-GST) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P706040

	EGFR Protein, Human (Active, T790M, sf9, His-GST) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P705601

	EGFR Protein, Human (Active, ΔE746-A750, T790M, L858R, sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P706037

	EGFR Protein, Human (Active, C797S, L858R, sf9) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P700693

	CLEC14A Protein, Human (HEK293, His) epidermal growth factor receptor 5; EGFR-5; EGFR 5; EGFR5; C14orf27; UNQ236; PRO269; CEG1	Human	HEK293
	CLEC14A is a type I transmembrane protein belonging to the C-type lectin superfamily that mediates intercellular adhesion, inflammatory response, and apoptosis. CLEC14A is upregulated in hepatocellular carcinoma and may serve as a potential diagnostic biomarker. CLEC14A Protein, Human (HEK293, His) is the recombinant human-derived CLEC14A protein, expressed by HEK293 , with C-His labeled tag.

HY-P706039

	EGFR Protein, Human (Active, T790M, C797S, sf9, His-GST) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; ERBB; ERBB1; HER1	Human	Sf9 insect cells

HY-P705562

	EGFR Protein, Human (Active, L858R, sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EC:2.7.10.1	Human	Sf9 insect cells

HY-P705814

	EGFR Protein, Human (Active, G696-G1022, ΔE746-A750, T790M, C797S, sf9, Strep-GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	sf9 insect cells

HY-P705561

	EGFR Protein, Human (Active, ΔE746-A750, T790M, C797S, sf9, Strep-GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EC:2.7.10.1	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (7) Rabbit (1)
Reactivity:	Human (7) Rat (3) Mouse (3) Monkey (1)
Application:	IHC-P (6) ICC/IF (2) mIHC (1) IF-Tissue (4) IP (2) IHC-F (4) WB (8) FC (1)
Isotype:	IgG (3) IgG1 (3)
Conjugation:	Non-conjugated (8) Biotin (2)
Clonality:	Monoclonal (6) Recombinant (2)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85536

	GRB2 Antibody (YA5228) Abundant SRC homology; Adapter protein GRB2; ASH; Ash protein; EGFRBP GRB2; epidermal growth factor receptor binding protein; epidermal growth factor receptor binding protein GRB2; GRB 2; GRB2 adapter protein; Grb2; GRB2_human; Grb3 3; growth factor receptor bound protein 2; growth factor receptor bound protein 3; growth factor receptor-bound protein 2; HT027; MST084; MSTP084; NCKAP2; OTTHUMP00000166096; OTTHUMP00000166097; OTTHUMP00000166098; Protein ASH; SEM5; SH2/SH3 adapter GRB2.	WB	Human, Mouse, Rat
	GRB2 Antibody (YA5228) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to GRB2.

HY-P85600

	EGFR Antibody (YA5292) Avian erythroblastic leukemia viral; v erb b; oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; EGFR_human; epidermal growth factor receptor; avian erythroblastic leukemia viral; v erb b; oncogene homolog; epidermal growth factor receptor; erythroblastic leukemia viral; v erb b; oncogene homolog avian; epidermal growth factor receptor; erbb 1; Erbb; Erbb1; ERBB1; Errp; HER1; mENA; Oncogene ERBB; PIG61; Proto-oncogene c-ErbB-1; receptor tyrosine protein kinase ErbB 1; receptor tyrosine-protein kinase ErbB-1; Urogastrone; wa2; Wa5.	WB, IHC-P, ICC/IF, IP	Human, Monkey
	EGFR Antibody (YA5292) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to EGFR.

HY-P86718

	EGFR Antibody (YA6410) EGFR; Avian erythroblastic leukemia viral(v erb b) oncogene homolog; Avian erythroblastic leukemia viral(verbb) oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; epidermal growth factor receptor(avian erythroblastic leukemia viral(v erb b) oncogene homolog); epidermal growth factor receptor(erythroblastic leukemia viral(v erb b) oncogene homolog avian); epidermal growth factor receptor; erbb 1; Erbb; Erbb1; HER1; mENA; Oncogene ERBB; PIG61; receptor tyrosine protein kinase ErbB 1; receptor tyrosine protein kinase ErbB1; Urogastrone; wa2; Wa5; EGFR_human.	WB, IHC-P, IHC-F, IF-Tissue	Human
	EGFR Antibody (YA6410) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to EGFR.

HY-P86718A

	EGFR Antibody (YA6410)(PBS only) EGFR; Avian erythroblastic leukemia viral(v erb b) oncogene homolog; Avian erythroblastic leukemia viral(verbb) oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; epidermal growth factor receptor(avian erythroblastic leukemia viral(v erb b) oncogene homolog); epidermal growth factor receptor(erythroblastic leukemia viral(v erb b) oncogene homolog avian); epidermal growth factor receptor; erbb 1; Erbb; Erbb1; HER1; mENA; Oncogene ERBB; PIG61; receptor tyrosine protein kinase ErbB 1; receptor tyrosine protein kinase ErbB1; Urogastrone; wa2; Wa5; EGFR_human.	WB, IHC-P, IHC-F, IF-Tissue	Human
	EGFR Antibody (YA6410) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to EGFR.

HY-P86948

	LRP4 Antibody (YA6641) KIAA0816 antibody; LDLR dan antibody; Low density lipoprotein receptor related protein 4 antibody; Low-density lipoprotein receptor-related protein 4 antibody; LRP-4 antibody; LRP10 antibody; Lrp4 antibody; LRP4_human antibody; MEGF7 antibody; Multiple epidermal growth factor like domains 7 antibody; KIAA0816 antibody; LDLR dan antibody; Low density lipoprotein receptor related protein 4 antibody; Low-density lipoprotein receptor-related protein 4 antibody; LRP-4 antibody; LRP10 antibody; Lrp4 antibody; LRP4_human antibody; MEGF7 antibody; Multiple epidermal growth factor like domains 7 antibody; Multiple epidermal growth factor-like domains 7 antibody;	WB	Mouse, Rat
	LRP4 Antibody (YA6641) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRP4.

HY-P80116

	EGFR Antibody (YA468) 1 Publications Verification Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody; Cell growth inhibiting protein 40 antibody; Cell proliferation inducing protein 61 antibody; EGF R antibody; EGFR antibody; EGFR_human antibody; epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody; epidermal growth factor receptor antibody; erb-b2 receptor tyrosine kinase 1 antibody; ERBB antibody; ERBB1 antibody; Errp antibody; HER1 antibody; mENA antibody; NISBD2 antibody; Oncogen ERBB antibody; PIG61 antibody; Proto-oncogene c-ErbB-1 antibody; receptor tyrosine protein kinase ErbB 1 antibody; receptor tyrosine-protein kinase ErbB-1 antibody; SA7 antibody; Species antigen 7 antibody; Urogastrone antibody; v-erb-b Avian erythroblastic leukemia viral oncogen homolog antibody; wa2 antibody; Wa5 antibody	WB, IHC-P, ICC/IF, IP, FC, mIHC	Human, Mouse, Rat
	EGFR Antibody (YA468) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EGFR.

HY-P86719

	C-erbB-2/HER2 Antibody (YA6411) Erb-B2 receptor Tyrosine Kinase 2; NGL; NEU; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Tyrosine Kinase-Type Cell Surface receptor HER2; Neuro/Glioblastoma Derived Oncogene Homolog; human epidermal growth factor receptor 2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; EC 2.7.10.1; P185erbB2; MLN 19; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; receptor Tyrosine-Protein Kinase ErbB-2; C-Erb B2/Neu Protein; CD340 Antigen; Herstatin; EC 2.7.10; CD340; HER-2; MLN19; TKR1;	WB, IHC-P, IHC-F, IF-Tissue	Human
	C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P86719A

	C-erbB-2/HER2 Antibody (YA6411)(PBS only) Erb-B2 receptor Tyrosine Kinase 2; NGL; NEU; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Tyrosine Kinase-Type Cell Surface receptor HER2; Neuro/Glioblastoma Derived Oncogene Homolog; human epidermal growth factor receptor 2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; EC 2.7.10.1; P185erbB2; MLN 19; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; receptor Tyrosine-Protein Kinase ErbB-2; C-Erb B2/Neu Protein; CD340 Antigen; Herstatin; EC 2.7.10; CD340; HER-2; MLN19; TKR1;	WB, IHC-P, IHC-F, IF-Tissue	Human
	C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-129510

4-Methyl erlotinib		Alkynes
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

Cat. No.	Product Name		Classification

HY-174535

Human TGFA mRNA		mRNA
Human TGFA mRNA encodes the human transforming growth factor alpha (TGFA) protein. TGFA is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development.

HY-174779

Human AREG mRNA		mRNA
Human AREG mRNA encodes the human amphiregulin (AREG) protein, a member of the epidermal growth factor family. AREG interacts with the EGF/TGF-alpha receptor to promote the growth of normal epithelial cells, and inhibits the growth of certain aggressive carcinoma cell lines. It also functions in mammary gland, oocyte and bone tissue development.

HY-174721

Human EGFR mRNA		mRNA
Human EGFR mRNA encodes the human epidermal growth factor receptor (EGFR) protein, a member of the protein kinase superfamily. IGF1R plays a critical role in transformation events. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: